1/12
10:04 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
1/12
02:40 am
cstl
The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook [Yahoo! Finance]
Low
Report
The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook [Yahoo! Finance]
1/12
01:41 am
cstl
Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth [Yahoo! Finance]
Low
Report
Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth [Yahoo! Finance]
1/11
07:40 pm
cstl
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results [Yahoo! Finance]
Low
Report
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results [Yahoo! Finance]
1/11
04:00 pm
cstl
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
Low
Report
Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results
1/6
07:25 am
cstl
Castle Biosciences (NASDAQ:CSTL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Castle Biosciences (NASDAQ:CSTL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
1/5
10:16 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/22
08:02 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $37.00 to $50.00. They now have a "buy" rating on the stock.
Medium
Report
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $37.00 to $50.00. They now have a "buy" rating on the stock.
12/19
07:00 am
cstl
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/18
07:33 pm
cstl
Is New Uveal Melanoma Data Elevating Castle Biosciences' DecisionDx-UM Platform Story (CSTL)? [Yahoo! Finance]
Low
Report
Is New Uveal Melanoma Data Elevating Castle Biosciences' DecisionDx-UM Platform Story (CSTL)? [Yahoo! Finance]
12/17
07:00 am
cstl
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
Low
Report
Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
12/13
02:18 pm
cstl
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]
Low
Report
Castle Biosciences (CSTL): Valuation Check After Expert Panel Endorses DecisionDx-Melanoma Test [Yahoo! Finance]
12/12
08:06 am
cstl
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its price target raised by analysts at BTIG Research from $38.00 to $50.00. They now have a "buy" rating on the stock.
12/12
07:39 am
cstl
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]
Low
Report
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer [Yahoo! Finance]
12/12
07:00 am
cstl
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
Low
Report
Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
12/9
07:00 am
cstl
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
Low
Report
Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma
11/21
07:04 pm
cstl
Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]
Medium
Report
Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? [Yahoo! Finance]
11/20
01:33 pm
cstl
Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Castle Biosciences (NASDAQ:CSTL) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
09:13 am
cstl
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]
Low
Report
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year [Yahoo! Finance]
11/17
07:00 am
cstl
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
Low
Report
Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
11/14
08:10 am
cstl
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]
Low
Report
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity [Yahoo! Finance]
11/14
07:00 am
cstl
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
Low
Report
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity
11/11
07:00 am
cstl
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
Low
Report
Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference
11/7
03:48 am
cstl
SciBase: Interim report [Yahoo! Finance]
Low
Report
SciBase: Interim report [Yahoo! Finance]
11/7
02:37 am
cstl
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million [Yahoo! Finance]
Low
Report
SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million [Yahoo! Finance]